Tumor Biology

, Volume 35, Issue 12, pp 11933–11938 | Cite as

Mir-155 promotes cervical cancer cell proliferation through suppression of its target gene LKB1

  • Guoying Lao
  • Ping Liu
  • Qiongwei Wu
  • Wenying Zhang
  • Yu Liu
  • Longtao Yang
  • Chengbin Ma
Research Article


MicroRNAs (miRNAs) are important regulators of many physiological and pathological processes, including cell proliferation, apoptosis, and cell cycle arrest. In this study, we aimed to investigate the biological role of miR-155 in cervical cancer and the underlying molecular mechanism involved in tumorigenesis. The expression of miR-155 in human cervical cancer tissues was detected by real-time PCR. MTT assay and BrdU incorporation assay were used to measure the proliferation of cervical cancer cells. Apoptosis cells and cell cycle distribution were analyzed by flow cytometry. We found that the expression of miR-155 was upregulated in cervical cancer tissues compared to the adjacent non-cancer tissues. Overexpression of miR-155 promoted the proliferation of Hela and SiHa cells. By contrast, downregulation of miR-155 inhibited the growth of cervical cancer cells. Flow cytometry analysis showed that low expression of miR-155 promoted apoptosis and induced cell cycle arrest in Hela and SiHa cells. Moreover, the mRNA and protein expression of LKB1 was significantly reduced in cervical cancer tissues. Luciferase reporter assay demonstrated that LKB1 was a target gene of miR-155, suggesting that miRNA-155 promoted the proliferation of cervical cancer cells by regulating LKB1 expression.


Cervical cancer Cell proliferation miR-155 LKB1 



This study was supported by Key Construction Project of Changning District Health Bureau, Shanghai.: Changning District Minimally Invasive Gynecologic Surgery Center (Project Number 2004105001)

Conflicts of interest



  1. 1.
    Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.PubMedCrossRefGoogle Scholar
  2. 2.
    Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127:2893–917.PubMedCrossRefGoogle Scholar
  3. 3.
    Wang X, Tang S, Le SY, Lu R, Rader JS, Meyers C, et al. Aberrant expression of oncogenic and tumor-suppressive microRNAs in cervical cancer is required for cancer cell growth. PLoS One. 2008;3:e2557.PubMedCentralPubMedCrossRefGoogle Scholar
  4. 4.
    Li Y, Wang F, Xu J, Ye F, Shen Y, Zhou J, et al. Progressive miRNA expression profiles in cervical carcinogenesis and identification of HPV-related target genes for miR-29. J Pathol. 2011;224:484–95.PubMedCrossRefGoogle Scholar
  5. 5.
    Colombo N, Carinelli S, Colombo A, Marini C, Rollo D, Sessa C. Cervical cancer: esmo clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012;23 Suppl 7:i27–32.Google Scholar
  6. 6.
    Hwang HW, Mendell JT. MicroRNAs in cell proliferation, cell death, and tumorigenesis. Br J Cancer. 2007;96(Suppl):R40–4.PubMedGoogle Scholar
  7. 7.
    Tamura M, Uyama M, Sugiyama Y, Sato M. Canonical Wnt signaling activates miR-34 expression during osteoblastic differentiation. Mol Med Rep. 2013;8:1807–11.PubMedGoogle Scholar
  8. 8.
    Vasudevan S, Tong Y, Steitz JA. Switching from repression to activation: microRNAs can up-regulate translation. Science. 2007;318:1931–4.PubMedCrossRefGoogle Scholar
  9. 9.
    Bandres E, Agirre X, Bitarte N, Ramirez N, Zarate R, Roman-Gomez J, et al. Epigenetic regulation of microRNA expression in colorectal cancer. Int J Cancer. 2009;125:2737–43.PubMedCrossRefGoogle Scholar
  10. 10.
    Marcucci G, Maharry KS, Metzeler KH, Volinia S, Wu YZ, Mrozek K, et al. Clinical role of microRNAs in cytogenetically normal acute myeloid leukemia: miR-155 upregulation independently identifies high-risk patients. J Clin Oncol. 2013;31:2086–93.PubMedCentralPubMedCrossRefGoogle Scholar
  11. 11.
    Yang M, Shen H, Qiu C, Ni Y, Wang L, Dong W, et al. High expression of mir-21 and mir-155 predicts recurrence and unfavourable survival in non-small cell lung cancer. Eur J Cancer. 2013;49:604–15.PubMedCrossRefGoogle Scholar
  12. 12.
    Jiang S, Zhang HW, Lu MH, He XH, Li Y, Gu H, et al. MicroRNA-155 functions as an OncomiR in breast cancer by targeting the suppressor of cytokine signaling 1 gene. Cancer Res. 2010;70:3119–27.PubMedCrossRefGoogle Scholar
  13. 13.
    Pedersen IM, Otero D, Kao E, Miletic AV, Hother C, Ralfkiaer E, et al. Onco-mir-155 targets SHIP1 to promote TNFalpha-dependent growth of B cell lymphomas. EMBO Mol Med. 2009;1:288–95.PubMedCentralPubMedCrossRefGoogle Scholar
  14. 14.
    Costinean S, Sandhu SK, Pedersen IM, Tili E, Trotta R, Perrotti D, et al. Src homology 2 domain-containing inositol-5-phosphatase and CCAAT enhancer-binding protein beta are targeted by miR-155 in B cells of Emicro-MiR-155 transgenic mice. Blood. 2009;114:1374–82.PubMedCentralPubMedCrossRefGoogle Scholar
  15. 15.
    Gocze K, Gombos K, Juhasz K, Kovacs K, Kajtar B, Benczik M, et al. Unique microRNA expression profiles in cervical cancer. Anticancer Res. 2013;33:2561–7.PubMedGoogle Scholar
  16. 16.
    Gironella M, Seux M, Xie MJ, Cano C, Tomasini R, Gommeaux J, et al. Tumor protein 53-induced nuclear protein 1 expression is repressed by miR-155, and its restoration inhibits pancreatic tumor development. Proc Natl Acad Sci U S A. 2007;104:16170–5.PubMedCentralPubMedCrossRefGoogle Scholar
  17. 17.
    Huang X, Taeb S, Jahangiri S, Emmenegger U, Tran E, Bruce J, et al. MiRNA-95 mediates radioresistance in tumors by targeting the sphingolipid phosphatase SGPP1. Cancer Res. 2013;73:6972–86.PubMedCrossRefGoogle Scholar
  18. 18.
    Li T, Kon N, Jiang L, Tan M, Ludwig T, Zhao Y, et al. Tumor suppression in the absence of p53-mediated cell-cycle arrest, apoptosis, and senescence. Cell. 2012;149:1269–83.PubMedCentralPubMedCrossRefGoogle Scholar
  19. 19.
    Glienke W, Maute L, Wicht J, Bergmann L. The dual PI3k/mTOR inhibitor NVP-BGT226 induces cell cycle arrest and regulates survivin gene expression in human pancreatic cancer cell lines. Tumour Biol. 2012;33:757–65.PubMedCrossRefGoogle Scholar
  20. 20.
    Higgs G, Slack F. The multiple roles of microRNA-155 in oncogenesis. J Clin Bioinforma. 2013;3:17.PubMedCentralPubMedCrossRefGoogle Scholar
  21. 21.
    Wingo SN, Gallardo TD, Akbay EA, Liang MC, Contreras CM, Boren T, et al. Somatic LKB1 mutations promote cervical cancer progression. PLoS One. 2009;4:e5137.PubMedCentralPubMedCrossRefGoogle Scholar
  22. 22.
    Ji H, Ramsey MR, Hayes DN, Fan C, McNamara K, Kozlowski P, et al. LKB1 modulates lung cancer differentiation and metastasis. Nature. 2007;448:807–10.PubMedCrossRefGoogle Scholar
  23. 23.
    Shah U, Sharpless NE, Hayes DN. LKB1 and lung cancer: more than the usual suspects. Cancer Res. 2008;68:3562–5.PubMedCrossRefGoogle Scholar
  24. 24.
    Martin SG, St JD. A role for drosophila LKB1 in anterior-posterior axis formation and epithelial polarity. Nature. 2003;421:379–84.PubMedCrossRefGoogle Scholar
  25. 25.
    Shackelford DB, Shaw RJ. The LKB1-ampk pathway: metabolism and growth control in tumour suppression. Nat Rev Cancer. 2009;9:563–75.PubMedCentralPubMedCrossRefGoogle Scholar
  26. 26.
    Green AS, Chapuis N, Lacombe C, Mayeux P, Bouscary D, Tamburini J. LKB1/AMPK/mTOR signaling pathway in hematological malignancies: from metabolism to cancer cell biology. Cell Cycle. 2011;10:2115–20.PubMedCrossRefGoogle Scholar
  27. 27.
    Zhang X, Chen H, Wang X, Zhao W, Chen JJ. Expression and transcriptional profiling of the LKB1 tumor suppressor in cervical cancer cells. Gynecol Oncol. 2014.Google Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2014

Authors and Affiliations

  • Guoying Lao
    • 1
  • Ping Liu
    • 1
  • Qiongwei Wu
    • 1
  • Wenying Zhang
    • 1
  • Yu Liu
    • 1
  • Longtao Yang
    • 1
  • Chengbin Ma
    • 1
  1. 1.Department of GynecologyChangning Maternity and Infant Health Hospital of ShanghaiShanghaiChina

Personalised recommendations